Skip to content

Minimizing Risk and Maximizing Outcomes in Geriatric Patients Through Integrated Clinical Pharmacy Services in an Innovative Model of Community Practice

Minimizing Risk and Maximizing Outcomes in Geriatric Patients Through Integrated Clinical Pharmacy Services in an Innovative Model of Community Practice

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01351441
Enrollment
20
Registered
2011-05-10
Start date
2011-05-31
Completion date
2012-11-30
Last updated
2020-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Geriatric Patient Care Improvement, Health Literacy, Medication Adherence, Pharmacy Economic Improvement

Keywords

Geriatric, Pharmacoeconomics, Health Literacy, Adherence

Brief summary

It has been shown that patients can improve their safety through informed choice, safe medication use, and complication reporting. This includes not only the potential problems that occur from prescription medication use but also issues that may arise through the improper use of over-the-counter medications. The willingness of a patient to take on safety action is known to be complicated by an unwillingness to behave in a manner that might challenge a physician's judgment or actions. Community pharmacists are in the unique position to provide perspective on the physician's recommendation and act as an advocate to facilitate necessary change. Through supportive and repeated interaction with their community pharmacist patients will develop assertiveness toward their own health care, an increased frequency and quality of interaction with their physician, and thus a minimized risk of harm and maximized opportunity to optimize clinical outcomes.

Detailed description

This is a single center, observational study to determine if geriatric patients who are on five or more chronic medications will have a difference in clinical, humanistic, and/or economic outcome through an integrated clinical pharmacy service intervention. The primary efficacy objective will be assessed through a single cohort, paired research design measuring the change from baseline in the adherence rate, number of medication related problems, and Beers criteria medications. The primary economic objective will be assessed through prescription revenue to validate the employment of a 0.5-1.0 Full-time equivalent (FTE). Secondary efficacy objectives will be assessed through a single cohort, paired research design measuring the change from baseline in the health literacy, optimization in the anthropometrics, and health related quality of life (HRQOL).

Interventions

BEHAVIORALMedication adherence consultation

Patients will be counseled in person on day 0 then telephonically every month after until day 365.

OTHERMedication problems assessment

Patients will be asked if they are having any issues that may be attributable to their current drug therapy on a monthly basis. Any issue that is identified will be addressed by the pharmacist.

OTHERBeer's Criteria Assessment

The patient's drug therapy will be reviewed for Beer's criteria medications and possible alternatives will be addressed by the pharmacist if deemed appropriate.

Patients will be given a Health Literacy Assessment on day 0 and day 365 using the Realm-SF.

Sponsors

Community Pharmacy Foundation
CollaboratorOTHER
VascuScript Pharmacy
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Patients who are at least 65 years of age * Have at least 5 medications that they take on a chronic basis * Willing to have their prescriptions filled by VascuScript Pharmacy * Understand the terms of the informed consent

Exclusion criteria

* Any patient who does not meet the requirements of the Inclusion Criteria

Design outcomes

Primary

MeasureTime frameDescription
Medication adherenceEvery 30 days for 12 monthsTo determine if an integrated clinical pharmacy service program in geriatric patients can maintain a medication adherence rate ≥80%.
Medication related problemsEvery 30 days for 12 monthsTo determine if an integrated clinical pharmacy service program in geriatric patients can reduce the number of medication related problems by ≥10%.
Beers criteria medicationsEvery month for 12 monthsTo determine if an integrated clinical pharmacy service program in geriatric patients can reduce the number of Beers criteria medications by ≥10%.
Economic impact12 monthsTo determine the number of patients required to validate a part-time or full-time pharmacist to perform the required clinical functions of the clinical pharmacy service geriatric program.

Secondary

MeasureTime frameDescription
Optimizing Anthropometrics12 monthsTo determine if an integrated clinical pharmacy service program in geriatric patients can demonstrate ≥10% improvement and/or greater optimization of patient weight, blood pressure, cholesterol, and blood glucose (if applicable).
Quality of Life12 monthsTo determine if an integrated clinical pharmacy service program in geriatric patients can improve quality of life as evidenced by the CDC HRQOL Healthy Days Core Module.
Health literacy12 monthsTo determine if an integrated clinical pharmacy service program in geriatric patients can improve health literacy as evidenced by the REALM-SF.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026